ETFs & Funds
View as an RSS Feed
Why I Believe Oncothyreon Is The Stock To Own Into 2013
Oncothyreon a small Company that has a Phase III trials for a development vaccine BLP25 for small cell lung cancer which target Muc1 inhibitor will deliver results at the end of March 2013 as the price per share does not reflect real value of a success of the start trial. It presents a huge opportunity for investors to buy at a 52 week low,with limited risk on the down side due to the 52 week low under 5 considering Oncothyreon has ONT-10 on the pipeline which will also deliver results around the same time. Measuring the success of a start trial with and taking in to consideration the short interest in Oncothyreon is up to 22% plus buying pressure might have nice gains Oncothyreon could be caught in a short squeeze with good news on start trial or even a partnership on ONT- 10 could deliver huge upside gains for investors considering the risk, there are many good indicators that might point for and upside trend following the market manipulation that this biotech is held under looking at the trend Onty opens with good volume and closes at a sell off . Option Volume tells us a different story ,however price per share does not reflect the Value of the possible gains investors in case a success of a start trial or even a partnership on ONT-10. I am long ONCOTHYREON and base this on my opinion only ,did not receive any monetary compensation for this article ,and do not recommend anyone to start any position in Oncothyreon with out doing their own diligence.
Dec 5, 2012. 01:43 AM
Link to Comment